Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Hydrea, Droxia, Siklos
Hydroxyurea is an antineoplastic antimetabolite medication used to treat various types of cancer, including chronic myeloid leukemia, ovarian cancer, and certain types of skin cancer. It works by inhibiting ribonucleotide reductase, an enzyme crucial for DNA synthesis, thereby slowing the growth of cancer cells. Hydroxyurea is also used in the management of sickle cell disease to reduce the frequency of painful crises.
Used to treat certain types of cancer and sickle cell disease.
Severe myelosuppression, including leukopenia, anemia, and thrombocytopenia, can occur. Secondary leukemia has been reported. Embryo-fetal toxicity has been observed. Patients should be advised to avoid becoming pregnant while taking hydroxyurea.
Outcome:
Increased risk of didanosine toxicity
Mechanism:
Inhibition of didanosine metabolism
Outcome:
Increased risk of adverse effects
Mechanism:
Pharmacokinetic interactions
Outcome:
May increase risk of skin rash
Mechanism:
Unknown
Most likely new formulation: controlled-release formulation (Year 2025, 80% confidence)
Based on current usage trends and clinical trial data, there is a 70% likelihood of expanded indications for hydroxyurea in the next 5 years.
Antineoplastic, Antimetabolite
Hydroxyurea